Genesis MedTech Buys JC Medical

Genesis MedTech has acquired JC Medical (JCM), a structural heart company mainly focused on transcatheter valve replacement devices. Genesis has added the J-Valve transcatheter aortic valve replacement (TAVR) device for aortic regurgitation and stenosis to its portfolio.
 
According to JCM, J-Valve is one of only two minimally invasive TAVR devices approved for both aortic regurgitation and stenosis. Its design minimizes stent migration, and can treat a wider patient pool including those with low coronary ostium height and small sinuses. It can also cater to those needing aortic and mitral valve-in-valve surgeries.
 
JCM founder and president Zhang Ji will continue his role as JCM president. He will also become chief technology officer for Genesis’ structural heart business.
 
J-Valve is available in both transapical (J-Valve TA) and transfemoral (J-Valve TF) TAVR approaches. To date, J-Valve has been successfully used in over 3,000 patients in China, with over 1,000 last year.
 
J-Valve TF is currently limited to compassionate use in the U.S. and Canada. The device has over 20 valve implants to date. It’s undergoing clinical trials in the U.S.
 
“The acquisition of JCM and J-Valve exemplifies the type of innovations we envisage as part of a growing Genesis portfolio,” Warren Wang, Chairman and CEO of Genesis told the press. “We are incredibly pleased to start a new Structural Heart Franchise, spearheaded by the best-in-class TAVR solution, J-Valve. By doing this we hope to better support cardiac surgeons and cardiologists in their fight against structural heart diseases.”